Jun 18, 2020
RINVOQ(TM) (upadacitinib) Monotherapy Shows Improvement in Skin Clearance and Itch in First Phase 3 Study for Atopic Dermatitis
Jun 15, 2020
Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients
Jun 12, 2020
Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib
Jun 03, 2020
EULAR 2020: Lilly Shares New Data for Olumiant® in Rheumatoid Arthritis and Systemic Lupus Erythematosus
May 27, 2020
Sierra Oncology Announces Presentations at Upcoming Investor Conferences
May 26, 2020
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer
May 14, 2020
Sierra Oncology to Report Favorable Dose Intensity Data and Long-Term Safety Data for Momelotinib at the 25th European Hematology Association (EHA) Congress
May 07, 2020
Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis
May 07, 2020
TWi Biotechnology Receives Canada Health Approval for AC-1101 Phase 1 CTA
Apr 10, 2020
Lilly Begins Clinical Testing of Therapies for COVID-19
Mar 24, 2020
Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted
Mar 17, 2020
US Dermatologists Anticipate the Future of Atopic Dermatitis to Mirror that of the Over-Crowded Psoriasis Market
Feb 26, 2020
Sierra Oncology to Hold Year End 2019 & 2020 Outlook Analyst & Investor Call
Feb 25, 2020
Sierra Oncology to Present at the Cowen 40th Annual Health Care Conference
Feb 06, 2020
Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to Gilead
Jan 27, 2020
Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine
Dec 23, 2019
Portola Pharmaceuticals to Webcast Corporate Update on January 14, 2020
Dec 16, 2019
Promising Early Launch Metrics for AbbVie's Rinvoq (upadacitinib) to Help JAK Inhibitors Solidify Their Position as Second-Line Leaders in Rheumatoid Arthritis, According to Spherix Global Insights
Dec 08, 2019
Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies
Dec 07, 2019
Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting